Targeting	O
tumor	B:C0027651
tolerance	O
:	O
A	O
new	O
hope	O
for	O
pancreatic	O
cancer	I:C0235974
therapy	O
?.	O

Targeting	O
tumor	O
tolerance	O
:	O
A	O
new	O
hope	O
for	O
pancreatic	B:C0235974
cancer	I:C0235974
therapy	O
?.	O

Targeting	O
tumor	O
tolerance	O
:	O
A	O
new	O
hope	O
for	O
pancreatic	O
cancer	I:C0235974
therapy	B:C0087111
?.	O

With	O
a	O
5	O
-	O
year	O
survival	O
rate	O
of	O
just	O
8	O
%	O
,	O
pancreatic	B:C0235974
cancer	I:C0235974
(	O
pancreatic	O
cancer	I:C0235974
)	O
is	O
projected	O
to	O
be	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
deaths	O
by	O
2030	O
.	O

With	O
a	O
5	O
-	O
year	O
survival	O
rate	O
of	O
just	O
8	O
%	O
,	O
pancreatic	O
cancer	I:C0235974
(	O
pancreatic	B:C0235974
cancer	I:C0235974
)	O
is	O
projected	O
to	O
be	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
deaths	O
by	O
2030	O
.	O

Most	O
pancreatic	B:C0235974
cancer	I:C0235974
patients	O
are	O
not	O
eligible	O
for	O
surgery	O
with	O
curative	O
intent	I:C1276305
upon	O
diagnosis	O
,	O
emphasizing	O
a	O
need	O
for	O
more	O
effective	O
therapies	O
.	O

Most	O
pancreatic	O
cancer	I:C0235974
patients	O
are	O
not	O
eligible	O
for	O
surgery	B:C0543467
with	O
curative	O
intent	I:C1276305
upon	O
diagnosis	O
,	O
emphasizing	O
a	O
need	O
for	O
more	O
effective	O
therapies	O
.	O

Most	O
pancreatic	O
cancer	I:C0235974
patients	O
are	O
not	O
eligible	O
for	O
surgery	O
with	O
curative	B:C1276305
intent	I:C1276305
upon	O
diagnosis	O
,	O
emphasizing	O
a	O
need	O
for	O
more	O
effective	O
therapies	O
.	O

Most	O
pancreatic	O
cancer	I:C0235974
patients	O
are	O
not	O
eligible	O
for	O
surgery	O
with	O
curative	O
intent	I:C1276305
upon	O
diagnosis	B:C0011900
,	O
emphasizing	O
a	O
need	O
for	O
more	O
effective	O
therapies	O
.	O

Most	O
pancreatic	O
cancer	I:C0235974
patients	O
are	O
not	O
eligible	O
for	O
surgery	O
with	O
curative	O
intent	I:C1276305
upon	O
diagnosis	O
,	O
emphasizing	O
a	O
need	O
for	O
more	O
effective	O
therapies	B:C0087111
.	O

However	O
,	O
pancreatic	B:C0235974
cancer	I:C0235974
is	O
notoriously	O
resistant	O
to	O
chemoradiation	O
regimens	O
.	O

However	O
,	O
pancreatic	O
cancer	I:C0235974
is	O
notoriously	O
resistant	B:C1514892
to	O
chemoradiation	O
regimens	O
.	O

As	O
an	O
alternative	O
,	O
immune	B:C0678889
modulating	I:C0678889
strategies	O
have	O
recently	O
achieved	O
success	O
in	O
melanoma	O
,	O
prompting	O
their	O
application	O
to	O
other	O
solid	O
tumors	I:C0280100
.	O

As	O
an	O
alternative	O
,	O
immune	O
modulating	I:C0678889
strategies	O
have	O
recently	O
achieved	O
success	O
in	O
melanoma	B:C0025202
,	O
prompting	O
their	O
application	O
to	O
other	O
solid	O
tumors	I:C0280100
.	O

As	O
an	O
alternative	O
,	O
immune	O
modulating	I:C0678889
strategies	O
have	O
recently	O
achieved	O
success	O
in	O
melanoma	O
,	O
prompting	O
their	O
application	O
to	O
other	O
solid	B:C0280100
tumors	I:C0280100
.	O

For	O
such	O
therapeutic	B:C0087111
approaches	O
to	O
succeed	O
,	O
a	O
state	O
of	O
immunologic	O
tolerance	I:C0020963
must	O
be	O
reversed	O
in	O
the	O
tumor	O
microenvironment	O
and	O
that	O
has	O
been	O
especially	O
challenging	O
in	O
pancreatic	O
cancer	I:C0235974
.	O

For	O
such	O
therapeutic	O
approaches	B:C0449445
to	O
succeed	O
,	O
a	O
state	O
of	O
immunologic	O
tolerance	I:C0020963
must	O
be	O
reversed	O
in	O
the	O
tumor	O
microenvironment	O
and	O
that	O
has	O
been	O
especially	O
challenging	O
in	O
pancreatic	O
cancer	I:C0235974
.	O

For	O
such	O
therapeutic	O
approaches	O
to	O
succeed	O
,	O
a	O
state	O
of	O
immunologic	B:C0020963
tolerance	I:C0020963
must	O
be	O
reversed	O
in	O
the	O
tumor	O
microenvironment	O
and	O
that	O
has	O
been	O
especially	O
challenging	O
in	O
pancreatic	O
cancer	I:C0235974
.	O

For	O
such	O
therapeutic	O
approaches	O
to	O
succeed	O
,	O
a	O
state	O
of	O
immunologic	O
tolerance	I:C0020963
must	O
be	O
reversed	O
in	O
the	O
tumor	O
microenvironment	O
and	O
that	O
has	O
been	O
especially	O
challenging	O
in	O
pancreatic	B:C0235974
cancer	I:C0235974
.	O

Nonetheless	O
,	O
knowledge	O
of	O
the	O
pancreatic	B:C0235974
cancer	I:C0235974
immune	O
microenvironment	O
has	O
advanced	O
considerably	O
over	O
the	O
past	O
decade	O
,	O
yielding	O
new	O
insights	O
and	O
perspectives	O
to	O
guide	O
multimodal	O
therapies	I:C0009429
.	O

Nonetheless	O
,	O
knowledge	O
of	O
the	O
pancreatic	O
cancer	I:C0235974
immune	O
microenvironment	O
has	O
advanced	O
considerably	O
over	O
the	O
past	O
decade	O
,	O
yielding	O
new	O
insights	B:C0233820
and	O
perspectives	O
to	O
guide	O
multimodal	O
therapies	I:C0009429
.	O

Nonetheless	O
,	O
knowledge	O
of	O
the	O
pancreatic	O
cancer	I:C0235974
immune	O
microenvironment	O
has	O
advanced	O
considerably	O
over	O
the	O
past	O
decade	O
,	O
yielding	O
new	O
insights	O
and	O
perspectives	O
to	O
guide	O
multimodal	B:C0009429
therapies	I:C0009429
.	O

In	O
this	O
review	O
,	O
we	O
catalog	B:C0376658
the	O
historical	O
groundwork	O
and	O
discuss	O
the	O
evolution	O
of	O
the	O
cancer	O
immunology	I:C1521825
field	O
to	O
its	O
present	O
state	O
with	O
a	O
specific	O
focus	O
on	O
pancreatic	O
cancer	I:C0235974
.	O

In	O
this	O
review	O
,	O
we	O
catalog	O
the	O
historical	O
groundwork	O
and	O
discuss	O
the	O
evolution	B:C0220825
of	O
the	O
cancer	O
immunology	I:C1521825
field	O
to	O
its	O
present	O
state	O
with	O
a	O
specific	O
focus	O
on	O
pancreatic	O
cancer	I:C0235974
.	O

In	O
this	O
review	O
,	O
we	O
catalog	O
the	O
historical	O
groundwork	O
and	O
discuss	O
the	O
evolution	O
of	O
the	O
cancer	B:C1521825
immunology	I:C1521825
field	O
to	O
its	O
present	O
state	O
with	O
a	O
specific	O
focus	O
on	O
pancreatic	O
cancer	I:C0235974
.	O

In	O
this	O
review	O
,	O
we	O
catalog	O
the	O
historical	O
groundwork	O
and	O
discuss	O
the	O
evolution	O
of	O
the	O
cancer	O
immunology	I:C1521825
field	O
to	O
its	O
present	O
state	O
with	O
a	O
specific	O
focus	O
on	O
pancreatic	B:C0235974
cancer	I:C0235974
.	O

Strategies	O
currently	O
employing	O
immune	B:C0678889
modulation	I:C0678889
in	O
pancreatic	O
cancer	I:C0235974
are	O
reviewed	O
,	O
specifically	O
highlighting	O
66	O
clinical	O
trials	I:C0008976
across	O
the	O
United	O
States	I:C0041703
and	O
Europe	O
.	O

Strategies	O
currently	O
employing	O
immune	O
modulation	I:C0678889
in	O
pancreatic	B:C0235974
cancer	I:C0235974
are	O
reviewed	O
,	O
specifically	O
highlighting	O
66	O
clinical	O
trials	I:C0008976
across	O
the	O
United	O
States	I:C0041703
and	O
Europe	O
.	O

Strategies	O
currently	O
employing	O
immune	O
modulation	I:C0678889
in	O
pancreatic	O
cancer	I:C0235974
are	O
reviewed	O
,	O
specifically	O
highlighting	O
66	O
clinical	B:C0008976
trials	I:C0008976
across	O
the	O
United	O
States	I:C0041703
and	O
Europe	O
.	O

Strategies	O
currently	O
employing	O
immune	O
modulation	I:C0678889
in	O
pancreatic	O
cancer	I:C0235974
are	O
reviewed	O
,	O
specifically	O
highlighting	O
66	O
clinical	O
trials	I:C0008976
across	O
the	O
United	B:C0041703
States	I:C0041703
and	O
Europe	O
.	O

Strategies	O
currently	O
employing	O
immune	O
modulation	I:C0678889
in	O
pancreatic	O
cancer	I:C0235974
are	O
reviewed	O
,	O
specifically	O
highlighting	O
66	O
clinical	O
trials	I:C0008976
across	O
the	O
United	O
States	I:C0041703
and	O
Europe	B:C0015176
.	O

